Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.
Cassondra Cramer-BourAmy Parker RuhlSeyed Mehdi NouraieRobert O EmehNicole F RuoppSwee Lay TheinNargues A WeirElizabeth S KlingsPublished in: European journal of haematology (2021)
In SCD patients with PH defined by RHC, PDE5-I therapy was tolerated long-term and may improve physical activity.